As the use of SGLT2 inhibitors is rapidly increasing in the treatment of T2D patients, their potential protective effect regarding the development of diabetic retinopathy through direct actions on retinal pericytes needs to be further investigated in clinical studies. Here, SLC5A2 is linked to diabetic retinopathy.